Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Ginzler, Ellen M
Siempos, Ilias I
Appel, Gerald B
Journal titleKidney international
Publication Begin page152
Publication End page60
MetadataShow full item record
AbstractClass V lupus nephritis (LN) occurs in one-fifth of biopsy-proven cases of systemic lupus erythematosus. To study the effectiveness of treatments in this group of patients, we pooled analysis of two large randomized controlled multicenter trials of patients with diverse ethnic and racial background who had pure class V disease. These patients received mycophenolate mofetil (MMF) or intravenous cyclophosphamide (IVC) as induction therapy for 24 weeks, with percentage change in proteinuria and serum creatinine as end points. Weighted mean differences, pooled odds ratios, and confidence intervals were calculated by using a random-effects model. A total of 84 patients with class V disease were divided into equal groups, each group had comparable entry variables but one received MMF and one received IVC. Within these groups, 33 patients on MMF and 32 patients on IVC completed 24 weeks of treatment. There were no differences between the groups in mean values for the measured end points. Similarly, no difference was found regarding the number of patients who did not complete the study or who died. In patients with nephrotic syndrome, no difference was noted between those treated with MMF and IVC regarding partial remission or change in urine protein. Hence we found that the response to MMF as induction treatment of patients with class V LN appears to be no different from that to IVC.
CitationRadhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010 Jan;77(2):152-60. doi: 10.1038/ki.2009.412. Epub 2009 Nov 4. PMID: 19890271.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
- Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
- Authors: Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, Shen P, Chen N
- Issue date: 2012 Apr
- Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
- Authors: Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L
- Issue date: 2007
- Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
- Authors: Prasad N, Kurian J, Agarwal V, Bhadauria D, Behera M, Yacha M, Kushwaha R, Agrawal V, Jain M, Gupta A
- Issue date: 2020 Jul
- Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial.
- Authors: Sundel R, Solomons N, Lisk L, Aspreva Lupus Management Study (ALMS) Group
- Issue date: 2012 Nov
- Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
- Authors: Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB
- Issue date: 2005 Nov 24